

Zydus receives final approval from the USFDA for Amantadine Hydrochloride Capsules

Ahmedabad, 01 June 2016

Zydus Cadila has received the final approval from the USFDA to market Amantadine Hydrochloride Capsules USP, 100 mg.

The estimated sales for Amantadine Hydrochloride Capsules USP as per IMS (*MAT April 2016*) is USD 40.1 million. The drug which is used in the treatment of Parkinson's disease and select viral infections, will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 100 approvals and has so far filed nearly 270 ANDAs since the commencement of the filing process in FY 2003-04.
